🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hanging out with the nephrologist

Those ICU call shifts remind me how much trust I put in my kidneys when it’s 10 pm and I have my first cup of water

Looking forward to meeting you all in a few short months! BIDMC IM Residency

Check out my first tweetorial on anticoagulation in this complex patient population! Many thanks to Adam Rodman and Brian Carney for their guidance BIDMC IM Residency #HemeTwitter #thrombosis

Incredibly grateful to continue the next phase of my training at BIDMC!

Welcome everybody to the BIDMC IM Residency family!

That "heading to the first session of the day" feeling. Jonathan Berry Ishan Tatake, MD #ASH22

Enjoying some time to relax after a challenging and rewarding first year of fellowship BIDMC Hematology/Oncology Fellowship very grateful for our tremendous leadership Deepa Rangachari, MD, FASCO Rushad Patell and Dr. Reed Drews

Another successful #ASH2023 BIDMC Hematology/Oncology Fellowship

A successful trip to Washington DC to learn from amazing educators and colleagues at the ASH Quality Improvement Training Institute - so thankful for this opportunity!! ASH BIDMC Hematology/Oncology Fellowship

This weekend, members of NBCA’s Council of Emerging Researchers in Thrombosis are presenting, Cancer-Associated Thrombosis: Understanding Awareness and Needs in the Community, at #ICTHIC2024 in Bergamo, Italy. Rushad Patell Ishan Tatake, MD Dana Angelini #stoptheclot

Grateful to NBCA and Rushad Patell for the opportunity to present our work surveying patient understanding and needs regarding cancer associated thrombosis at #ICTHIC2024

⭐️Ishan Tatake, MD BIDMC Hematology/Oncology Fellowship shares findings on how a diagnostic oncology clinic improves patient outcomes, including the potential for faster handoffs to a first oncology visit for patients admitted to the hospital with a new cancer diagnosis. #ASCOQLTY24

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis. Blood Journals Portfolio ashpublications.org/blood/article/…